Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

Conferencesofetabart mipitecanolomorasibNeutral

AI Analysis

Summary

Eli Lilly announced it will present oncology pipeline data at the 2026 ESMO Congress, including first Phase 1 data for FRα-targeting ADC sofetabart mipitecan in platinum-sensitive ovarian cancer and updated first-line data for KRAS G12C inhibitor olomorasib in NSCLC.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Lilly will present first Phase 1 data for sofetabart mipitecan (FRα-targeting ADC) in platinum-sensitive ovarian cancer as a rapid oral presentation, and updated first-line data for olomorasib in KRAS G12C-mutant NSCLC, at ESMO 2026.

Importance:5/10

Sentiment:

0.20

ESMOoncologyADCovarian cancerNSCLCKRAS G12CconferencePhase 1

Related Companies

$LLY

Read the original article

Published by PR Newswire Pharma on October 18, 2026 10:05 PM

Read Original